PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 479 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Common anti-inflammatory drug could boost cancer immunotherapy May 26, 2021 Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... January 20, 2022 Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal... September 19, 2024 ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology... June 19, 2026 Load more HOT NEWS Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death... De qué manera el seguimiento de los síntomas mejora la atención... Wishes for a New Year! Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer
